| Drug Name |
Glyburide |
| Drug ID |
BADD_D01030 |
| Description |
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.[L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin].[L8123] Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.[A183617]
Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120] |
| Indications and Usage |
Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.[L8120,L8123] |
| Marketing Status |
approved |
| ATC Code |
A10BB01 |
| DrugBank ID |
DB01016
|
| KEGG ID |
D00336
|
| MeSH ID |
D005905
|
| PubChem ID |
3488
|
| TTD Drug ID |
D05LYX
|
| NDC Product Code |
76333-154; 76333-155; 65691-0041; 23155-058; 0093-8034; 50090-0495; 51655-492; 65841-833; 68071-5217; 68382-658; 71209-011; 72241-039; 12579-056; 62147-0002; 50090-5776; 55700-725; 62135-584; 63187-848; 68071-3452; 70518-1646; 70934-690; 71335-0150; 12828-0066; 0093-8342; 0093-9477; 50090-6196; 62135-583; 62135-585; 68071-2189; 68788-8343; 71335-0069; 71209-009; 49452-3355; 0093-8036; 0093-9364; 53002-4170; 65841-834; 68382-656; 72241-040; 75834-204; 76333-156; 23155-056; 0009-0352; 0009-3449; 63187-659; 65841-832; 70518-3504; 65862-318; 68382-657; 75834-202; 43898-0001; 0093-8344; 0093-9433; 61919-378; 68071-2589; 23155-057; 68788-7970; 70518-1201; 46438-0059; 0009-0341; 63187-667; 70518-1513; 70934-855; 71209-010; 72241-038; 75834-203; 12579-054; 12579-055; 0093-8035; 0093-8343; 51655-659 |
| UNII |
SX6K58TVWC
|
| Synonyms |
Glyburide | Glybenclamide | Glibenclamide | Diabeta | Euglucon 5 | Neogluconin | HB-419 | HB 419 | HB419 | HB-420 | HB 420 | HB420 | Maninil | Micronase | Daonil | Euglucon N |
